Limited coverage drugs – aripiprazole monohydrate

aripiprazole monohydrate

300 mg, 400 mg

vial for injection

Management of the manifestations of schizophrenia or related psychotic disorders (not dementia-related) in:

1. Patients who have tried oral aripiprazole, risperidone or paliperidone

PLUS

at least one other antipsychotic agent

PLUS

continue to be inadequately controlled at maximally-tolerated doses

OR

2. Patients who are currently receiving a conventional depot antipsychotic

PLUS

experiencing significant side effects such as extrapyramidal symptoms or tardive dyskinesia

OR

3. Patients with a history of non-adherence to antipsychotic medications resulting in important negative outcomes such as repeated hospitalizations

Indefinite